Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.58 |
| ▸ | RARA | P10276 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808772 | 0.90 | RARB (0.49) | RARBRARAADRB3MCL1ADRB1 | |
| SCHEMBL6498950 | 0.82 | ADRB3 (0.60) | ADRB3MCL1ADRB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29032384 | 0.81 | PARP15 (0.48) | RARBRARAMCL1POLBALDH1A1 | |
| SCHEMBL2769244 | 0.79 | ADRB1 (0.55) | RARBRARAADRB3MCL1ADRB1 | |
| SCHEMBL1316077 | 0.78 | MCL1 (0.71) | MCL1POLBALDH1A1KDM4EMRGPRX4 | |
| SCHEMBL31406535 | 0.77 | ALDH1A1 (0.56) | ADRB3MCL1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL6496898 | 0.77 | KDM4E (0.53) | RARBRARAADRB3ADRB1ALDH1A1 | |
| SCHEMBL7865011 | 0.76 | MAOB (0.68) | RARBALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL19133762 | 0.76 | NR4A2 (0.58) | RARBMCL1KMT2APKMMRGPRX4 | |
| SCHEMBL17177743 | 0.76 | MCL1 (0.76) | MCL1POLBALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968991-A1 | BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY | Sede Secondaria Della Cell Therapeutics, Inc. (IT) | 2008-09-17 | — | — | EP | disclosed |
| US-7417169-B2 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| WO-2007071415-A1 | BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS, INC. - SEDE SECONDARIA (IT) | 2007-06-28 | — | — | WO | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679304-A1 | AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | RARB 667/4885RARA 630/4885ADRB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.